All In Biotech

Drug Trial Radar · NCT00111020

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,567

Actual

Start

Jun 2005

Primary completion

Jun 2007

Study completion Oct 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 17, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • Sorafenib (Nexavar, BAY43-9006)Drug

    Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety parametersTime frame: From signing consent to 30 days after last dose of study drug

Locations

320 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Bessemer, Alabama

  • Site not named

    Cullman, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Glendale, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Conway, Arkansas

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Pine Bluff, Arkansas

  • Site not named

    Springdale, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Beverly, California

  • Site not named

    Concord, California

  • Site not named

    Duarte, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Glendale, California

  • Site not named

    Highland, California

  • Site not named

    La Jolla, California

  • Site not named

    La Jolla, California

  • Site not named

    Loma Linda, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    Orange, California

  • Site not named

    Rancho Mirage, California

  • Site not named

    Sacramento, California

  • Site not named

    Salinas, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Stanford, California

  • Site not named

    Sunnyvale, California

  • Site not named

    Vallejo, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

Showing 40 of 320 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.